CNS market set to exceed $80 billion in 2025, driven by MS and psychiatric drug innovation
The global central nervous system (CNS) market is projected grow to over $80 billion in sales in 2025 for the first time since 2013, making a significant resurgence after a decade of stagnation.
This revival positions CNS as the fifth-fastest growing therapy area in 2025, driven by strong multiple sclerosis (MS) drug sales and renewed psychiatric drug innovation, according to pharma analytics company GlobalData.
The revival of CNS drug development is being fueled by advancements in neuroimmunology and neurodegeneration, moving beyond conventional dopamine and serotonin pathways. Leading the shift are from Swiss pharma giants Roche (ROG: SIX) with Ocrevus (ocrelizumab) and Novartis (NOVN: VX) with Kesimpta (ofatumumab) - two anti-CD20 monoclonal antibodies - expected to dominate the market. Ocrevus alone is forecasted to generate $8.1 billion in sales, accounting for nearly 10% of the total CNS revenue.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze